Cargando…
Psychosis in Alzheimer’s Disease
PURPOSE OF REVIEW: To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). RECENT FINDINGS: Psychosis in Alzheimer’s disease (AD) has an incidence of ~ 10% per year. There is limited evidence regarding psychological in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554014/ https://www.ncbi.nlm.nih.gov/pubmed/33048274 http://dx.doi.org/10.1007/s11910-020-01074-y |
_version_ | 1783593724625813504 |
---|---|
author | Ballard, Clive Kales, Helen C. Lyketsos, Constantine Aarsland, Dag Creese, Byron Mills, Roger Williams, Hilde Sweet, Robert A. |
author_facet | Ballard, Clive Kales, Helen C. Lyketsos, Constantine Aarsland, Dag Creese, Byron Mills, Roger Williams, Hilde Sweet, Robert A. |
author_sort | Ballard, Clive |
collection | PubMed |
description | PURPOSE OF REVIEW: To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). RECENT FINDINGS: Psychosis in Alzheimer’s disease (AD) has an incidence of ~ 10% per year. There is limited evidence regarding psychological interventions. Pharmacological management has focused on atypical antipsychotics, balancing modest benefits with evidence of long-term harms. The 5HT2A inverse agonist pimavanserin appears to confer benefit in PD psychosis with initial evidence of benefit in AD. Cholinesterase inhibitors give modest benefits in DLB psychosis. The utility of muscarinic agonists, lithium, glutamatergic and noradrenergic modulators needs further study. SUMMARY: Recent work has confirmed the importance of psychosis in MCI as well as AD. The lack of evidence regarding psychological therapies is an urgent knowledge gap, but there is encouraging evidence for emerging pharmacological treatments. Genetics will provide an opportunity for precision medicine and new treatment targets. |
format | Online Article Text |
id | pubmed-7554014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-75540142020-10-19 Psychosis in Alzheimer’s Disease Ballard, Clive Kales, Helen C. Lyketsos, Constantine Aarsland, Dag Creese, Byron Mills, Roger Williams, Hilde Sweet, Robert A. Curr Neurol Neurosci Rep Dementia (K.S. Marder, Section Editor) PURPOSE OF REVIEW: To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). RECENT FINDINGS: Psychosis in Alzheimer’s disease (AD) has an incidence of ~ 10% per year. There is limited evidence regarding psychological interventions. Pharmacological management has focused on atypical antipsychotics, balancing modest benefits with evidence of long-term harms. The 5HT2A inverse agonist pimavanserin appears to confer benefit in PD psychosis with initial evidence of benefit in AD. Cholinesterase inhibitors give modest benefits in DLB psychosis. The utility of muscarinic agonists, lithium, glutamatergic and noradrenergic modulators needs further study. SUMMARY: Recent work has confirmed the importance of psychosis in MCI as well as AD. The lack of evidence regarding psychological therapies is an urgent knowledge gap, but there is encouraging evidence for emerging pharmacological treatments. Genetics will provide an opportunity for precision medicine and new treatment targets. Springer US 2020-10-13 2020 /pmc/articles/PMC7554014/ /pubmed/33048274 http://dx.doi.org/10.1007/s11910-020-01074-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Dementia (K.S. Marder, Section Editor) Ballard, Clive Kales, Helen C. Lyketsos, Constantine Aarsland, Dag Creese, Byron Mills, Roger Williams, Hilde Sweet, Robert A. Psychosis in Alzheimer’s Disease |
title | Psychosis in Alzheimer’s Disease |
title_full | Psychosis in Alzheimer’s Disease |
title_fullStr | Psychosis in Alzheimer’s Disease |
title_full_unstemmed | Psychosis in Alzheimer’s Disease |
title_short | Psychosis in Alzheimer’s Disease |
title_sort | psychosis in alzheimer’s disease |
topic | Dementia (K.S. Marder, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554014/ https://www.ncbi.nlm.nih.gov/pubmed/33048274 http://dx.doi.org/10.1007/s11910-020-01074-y |
work_keys_str_mv | AT ballardclive psychosisinalzheimersdisease AT kaleshelenc psychosisinalzheimersdisease AT lyketsosconstantine psychosisinalzheimersdisease AT aarslanddag psychosisinalzheimersdisease AT creesebyron psychosisinalzheimersdisease AT millsroger psychosisinalzheimersdisease AT williamshilde psychosisinalzheimersdisease AT sweetroberta psychosisinalzheimersdisease |